Search research articles
Contact Us
Filters
Showing results (131-140 of 211) with videos related to
Page
of 22
Sort By:
Cancer Immunology, Immunotherapy : CII
|
March 2, 2024
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer
Gerald S Falchook, James Reeves, Sunil Gandhi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 14, 2018
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Neal Ready, Anna F Farago, Filippo de Braud, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 19, 2019
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
David E Gerber, D Ross Camidge, Daniel Morgensztern, et al.
The Oncologist
|
August 18, 2019
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial
David R Spigel, Dianna L Shipley, David M Waterhouse, et al.
Lung Cancer (Auckland, N.Z.)
|
November 16, 2017
<i>nab</i>-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
Michael Thomas, David R Spigel, Robert M Jotte, et al.
Targeted Oncology
|
November 2, 2024
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial
Erika P Hamilton, Gerald S Falchook, Judy S Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2023
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors
Christopher J Sweeney, John D Hainsworth, Ron Bose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2017
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update
Mark G Kris, Laurie E Gaspar, Jamie E Chaft, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 29, 2019
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
Makoto Nishio, Enriqueta Felip, Sergey Orlov, et al.
Cancer
|
February 23, 2022
RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer
Luis Paz-Ares, David R Spigel, Yuanbin Chen, et al.
Page
of 22
Search research articles
Search
Showing results (131-140 of 211) with videos related to
Sort By:
Page
of 22
Cancer Immunology, Immunotherapy : CII
|
March 2, 2024
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer
Gerald S Falchook, James Reeves, Sunil Gandhi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 14, 2018
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Neal Ready, Anna F Farago, Filippo de Braud, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 19, 2019
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer
David E Gerber, D Ross Camidge, Daniel Morgensztern, et al.
The Oncologist
|
August 18, 2019
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial
David R Spigel, Dianna L Shipley, David M Waterhouse, et al.
Lung Cancer (Auckland, N.Z.)
|
November 16, 2017
<i>nab</i>-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
Michael Thomas, David R Spigel, Robert M Jotte, et al.
Targeted Oncology
|
November 2, 2024
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial
Erika P Hamilton, Gerald S Falchook, Judy S Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2023
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors
Christopher J Sweeney, John D Hainsworth, Ron Bose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2017
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update
Mark G Kris, Laurie E Gaspar, Jamie E Chaft, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 29, 2019
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
Makoto Nishio, Enriqueta Felip, Sergey Orlov, et al.
Cancer
|
February 23, 2022
RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer
Luis Paz-Ares, David R Spigel, Yuanbin Chen, et al.
Page
of 22